AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00187122
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See Detailed Description section for description of treatment plan.
Trial: NCT01463397
Drug: SAR292833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT02843698
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT01110785
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01642771
Drug: Docetaxel/capecitabine followed by XEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
Trial: NCT03023878
Drug: Investigator's Choice Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the run-in period participants received 6 cycles of standard of care rituximab-chemotherapy dosed per investigator's institution standard as follows:~* R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)~* R-DA-EPOCH (rituximab and dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) or~* R-CHOEP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide).
Trial: NCT00656578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, solution
Trial: NCT03385369
Drug: MEDI0382
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of MEDI0382
Trial: NCT03385369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo
Trial: NCT01812837
Drug: Aminolevulinic Acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
Trial: NCT03029689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.
Trial: NCT03029689
Drug: Current ART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-drug antiretroviral treatment including PI/r/c or NNRTI
Trial: NCT02749799
Drug: DFD-01 (betamethasone dipropionate) Spray, 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
Trial: NCT00524693
Drug: Placebo granules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03111615
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated
Trial: NCT02634983
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
Trial: NCT02634983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT03705845
Drug: placebo softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.
Trial: NCT00010803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill twice daily
Trial: NCT00044525
Drug: BAY59-8862 (Cytotoxic Taxane)
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 h intravenous infusion every 3 weeks
Trial: NCT02684942
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Trial: NCT00523926
Drug: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01487239
Drug: [14C]-GDC-0980
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 uCi of \[14C\]-GDC-0980 in total dose of 10 mg GDC-0980
Trial: NCT03001466
Drug: urea-loaded nanoparticles eye drops
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop five times a day for 8 weeks
Trial: NCT03129295
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet four times a day for 3 days
Trial: NCT03152474
Drug: Solumedrol 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed Intravenous every 8 hrs.
Trial: NCT00002525
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perioperative 5-FU: 600 mg/m\^2/d x 7 days continuous IV, beginning within 24 hours of surgery~After surgery, 5-FU was given 425 mg/m\^2 IV push on days 1-5
Trial: NCT00002525
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given after surgery at dose of 20mg/m\^2 IV push on days 1-5
Trial: NCT05047484
Drug: ALXN2050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder-in-capsule (PIC).
Trial: NCT05047484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIC.
Trial: NCT01505179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
Trial: NCT00350779
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to sitagliptin 100mg tablet each day for 54 weeks.
Trial: NCT00543634
Drug: Premarin/MPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/2.5 mg X4
Trial: NCT00543634
Drug: Premarin/MPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/5 mg X 2
Trial: NCT02326740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02431832
Drug: Augmentin tab
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01369147
Drug: Parenteral Nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PN dose will be written for each 24-hr period taking into account any kilocalories (kcal) provided as part of standard of care from propofol, clevidipine, dextrose-containing IV fluid exceeding 500 mL/day, and enteral feedings.
Trial: NCT01369147
Drug: Enteral feeding
RxNorm normalized name: enteral feeding dispenser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition is caloric intake through the gastrointestinal (GI) tract via food consumed through the mouth or a feeding tube delivering nutrition directly to the stomach or small intestines. The PN dose will be written for each 24-hr period taking into account calories provided from any enteral feedings.
Trial: NCT01897792
Drug: Placebo (for Vitamin E)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill administered to mimic Vitamin E
Trial: NCT00911183
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00911183
Drug: liposome-encapsulated doxorubicin citrate
RxNorm normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01096680
Drug: SPD489 70 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 70 mg
Trial: NCT00203502
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg per meter squared, IV every 21 days
Trial: NCT02450279
Drug: technetium-99m - Diethylenetriaminepentaacetic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005908
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m\^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1
Trial: NCT01052623
Drug: Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
Trial: NCT00700050
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
Trial: NCT00005908
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m\^2 will be administered as a slow intravenous push on day 1
Trial: NCT00005908
Drug: Capecitabine - Dose B
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose B - Cohort 2 capecitabine 937.5 mg/m\^2 orally twice daily day 2-15
Trial: NCT00005908
Drug: Capecitabine - Dose A
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 1000 mg/m\^2 orally twice daily day 2-15 for 4 cycles
Trial: NCT03704506
Drug: Reyanning mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reyanning mixture , 20ml by mouth , 3 times per day for 7 days
Trial: NCT03704506
Drug: Reyanning mixture simulator
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reyanning mixture simulator , 20ml by mouth , 3 times per day for 7 days
Trial: NCT03704506
Drug: amoxil capsule simulator
RxNorm normalized name: Amoxi Drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxil capsule simulator , 0.5g by mouth , 3 times per day for 7 days
Trial: NCT03532776
Drug: Condylox Topical Gel 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
Trial: NCT03029845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take placebo twice a day for 2 weeks
Trial: NCT00511654
Drug: GW823296 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.
Trial: NCT01306409
Drug: cera, darbepoetin, epoetin-beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
Trial: NCT00511654
Drug: GW823296 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets will be identical in appearance to the GW823296 tablets.
Trial: NCT02970721
Drug: Antipsychotic
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic monotherapy
Trial: NCT02970721
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant monotherapy
Trial: NCT02956876
Drug: standard chemotherapy for colorectal cancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard chemotherapy for colorectal cancer
Trial: NCT01980745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05631782
Drug: Shenkang decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given Shenkang decoction on the basis of the above treatment. Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.
Trial: NCT02218671
Drug: WE 941 OD tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01776840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
Trial: NCT03532776
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
Trial: NCT01171885
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.9% saline
Trial: NCT00607789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical to study drug
Trial: NCT02488070
Drug: Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)
RxNorm normalized name: Gallium Ga 68-labeled psma ligand Glu-urea-Lys(ahx)-hbed-CC
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously-administered (IV) radioisotope
Trial: NCT04492787
Drug: Changkang Placebo Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take Changkang Placebo granule before meals twice a day , one bag for each time
Trial: NCT04387916
Drug: KC1036
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: Dose-escalation phase , KC1036 10mg\~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3\~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.
Trial: NCT03120949
Drug: Concomitant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.)~Folic acid ≥ 5 mg per week or equivalent
Trial: NCT04593771
Drug: BCG-PPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
Trial: NCT00515281
Drug: inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
Trial: NCT02536781
Drug: Anthocyanin
RxNorm normalized name: Anthocyanin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammation gel
Trial: NCT02536781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank gel
Trial: NCT02971683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Abatacept subcutaneous
Trial: NCT00303017
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: non-steroidal anti-inflammatory drug
Trial: NCT00621517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule nightly for six weeks
Trial: NCT03469999
Drug: Dysport Injectable Product
RxNorm normalized name: Dysport Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selected dose of medication will be determined by affected muscle(s), severity of spasticity, and the patient's body weight. We will follow the recommended total Dysport dose of 10-15 units/kg per limb, not to exceed 15 units/kg for unilateral lower limb, 30 units/kg for bilateral lower limb, or a total of 1000 units, whichever is lower in a given session.
Trial: NCT00739024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, oral, once daily
Trial: NCT02249013
Drug: Adjuvant Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
Trial: NCT02838589
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).
Trial: NCT02791438
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching azilsartan granules and tablets
Trial: NCT04746365
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatments
Trial: NCT02839876
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receives 1 g acetaminophen by the intravenous route every 6 hours for 4 doses beginning in the preoperative holding area.
Trial: NCT02839876
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receives 1 g acetaminophen by the oral route every 6 hours for 4 doses beginning in the preoperative holding area.
Trial: NCT01438372
Drug: Intravenous iron sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose will be administered on days 1, 7, 14, and 21 using the formula: Total dose: (normal Hb for age - initial Hb)/100 x blood volume (ml) x 3.4 x 1.5. First dose will be infused over 30 minutes, with subsequent doses administered over 15 minutes if no reactions encountered.
Trial: NCT03383692
Drug: DS-8201a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution
Trial: NCT00511459
Drug: AMG 386 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 Placebo \[blinded\]
Trial: NCT02414802
Drug: low-molecular-weight heparin calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge
Trial: NCT04453306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: innocuous substance is coated in tablets in an independent laboratory
Trial: NCT00660764
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT03528564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline to be administered to half of study participants (equal volume to Eprex x 1-2 subcutaneous injections)
Trial: NCT03201393
Drug: Low-dose naltrexone and acetaminophen combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twice a day
Trial: NCT03201393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day
Trial: NCT00384371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00586898
Drug: Testosterone transdermal gel
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an androgenic anabolic steroid
Trial: NCT01774929
Drug: TTS-fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
Trial: NCT01748851
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capecitabine 1000mg/m2 bid po D1-D14
Trial: NCT01748851
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
Trial: NCT00386802
Drug: Antifungal drug. VORICONAZOL. (VFEND®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)
Trial: NCT00471549
Drug: Statin (simvastatin)
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no